Mission Statement, Vision, & Core Values of IN8bio, Inc. (INAB)

A company's mission and values are the true measure of its long-term viability, especially in the high-stakes world of biotech where the financial runway is often short and the clinical path is long. IN8bio, Inc. (INAB) is defintely a case study in this, with its core vision of Cancer Zero™ driving a clinical-stage platform that must deliver results before its cash position runs dry.

You have to ask: can a company with a Q3 2025 net loss of $3.9 million and a cash balance of just $10.7 million as of September 30, 2025, truly sustain the mission of advancing novel gamma-delta T-cell therapies? The answer lies in how their foundational values translate into the clinical execution that has kept 100% of treated Acute Myeloid Leukemia (AML) patients in their INB-100 trial relapse-free. Does their commitment to scientific excellence outweigh the immediate pressure of a tiny $7.51 million market capitalization?

We're going to map out the company's explicit mission and core values, then connect them directly to the strategic decisions-like expanding the INB-100 trial to The Ohio State University-that are using those scarce dollars to chase their ambitious vision. This is how you assess the qualitative foundation of a highly volatile, nano-cap stock.

IN8bio, Inc. (INAB) Overview

You need to know where IN8bio, Inc. (INAB) stands right now: they are a clinical-stage biopharmaceutical company, founded in 2016, that is not generating product revenue but is posting significant clinical wins that drive its valuation. The company's mission is ambitious-they call it CANCER ZERO-which is the total elimination of all cancer cells in every patient, and they are pursuing it by pioneering gamma-delta T cell therapies.

IN8bio focuses on leveraging the unique, naturally occurring anti-cancer properties of gamma-delta T cells, which are immune cells that can differentiate between healthy and diseased tissue. Their core technology is the proprietary DeltEx™ platform, which is the engine for their pipeline of autologous (patient-derived), allogeneic (off-the-shelf), and genetically modified cell therapies.

As of November 2025, their business is centered on advancing these therapies through clinical trials, not commercial sales. They reported No revenue in the second quarter of 2025, which is typical for a company at this stage. The value is in the clinical data, specifically:

• INB-200 for newly diagnosed Glioblastoma (GBM): Showed a median Progression-Free Survival (PFS) of 16.1 months as of May 2025, which is more than double the 6.9 months seen with the standard-of-care Stupp protocol.
• INB-100 for high-risk Acute Myeloid Leukemia (AML): Demonstrated that 100% of treated AML patients remained relapse-free with a median follow-up of 20.1 months as of January 2025.

The science is defintely the story here.

2025 Fiscal Year Financial Performance and Cost Management

Looking at the latest financial reports, IN8bio is executing a clear strategy: prioritize the most promising clinical assets and aggressively manage the cash burn rate. They released their Q3 2025 earnings on November 6, 2025, reporting an Earnings Per Share (EPS) of -$0.85. This loss actually beat analysts' consensus estimates of -$1.20 by $0.35, showing better-than-expected cost control.

Here's the quick math on their operational discipline: in the second quarter of 2025, the company's net loss narrowed significantly to $5.1 million, a sharp improvement from the $8.6 million net loss in the comparable prior year period. This wasn't magic; it was a strategic reduction in spending following a pipeline prioritization announced in late 2024.

The expense breakdown for Q2 2025 highlights the shift:

• Research and Development (R&D) expenses fell to $2.5 million from $5.2 million in Q2 2024.
• General and Administrative (G&A) expenses declined to $2.7 million from $3.5 million in the prior-year period.

This focus on efficiency is critical for a clinical-stage biotech. As of June 30, 2025, the company held $13.2 million in cash, which management projected in August 2025 would fund operations into June 2026. That cash runway extension is the real win for investors in the near-term.

IN8bio: A Leader in Gamma-Delta T Cell Therapy

IN8bio is not just another biotech; they are positioned as one of the most advanced companies in the niche but rapidly growing field of gamma-delta T cell therapy. Their claim to leadership is grounded in being the first company to advance genetically modified gamma-delta T cells into the clinic, which is a major technical and regulatory milestone. They are redefining the landscape of cell therapy.

The clinical data for INB-200 in glioblastoma-a disease where new drugs have been scarce-is a powerful differentiator. Achieving a median PFS of 16.1 months, compared to the 6.9 months standard, is a concrete example of the transformative potential of their DeltEx™ platform. Plus, their manufacturing capabilities were recognized with an industry award in 2025 for their automated and scalable production process.

The company is strategically moving beyond just oncology, too, with promising preclinical data for their INB-619 gamma-delta T cell engager in autoimmune diseases like lupus, showcasing the platform's broad potential. To understand the granular details of how they are managing their capital and what this means for their stock, you should read Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors.

IN8bio, Inc. (INAB) Mission Statement

You want to know what drives a clinical-stage biopharmaceutical company like IN8bio, Inc. (INAB) and how their mission translates into tangible progress. The direct takeaway is this: IN8bio's mission is to develop novel therapies to address cancer, and its long-term goal is encapsulated in its aspirational vision of CANCER ZERO™. This isn't just a slogan; it's the strategic compass guiding their substantial investment in a specific, high-potential area of cell therapy.

The company's purpose, established in 2016, is to harness the body's immune system to fundamentally change how cancer is treated. This mission is the filter for every capital allocation decision, especially as a development-stage company. For example, Q3 2025 saw Research and Development (R&D) expenses at $2.1 million, down from $2.5 million in Q2 2025, reflecting a strategic pipeline prioritization that directly aligns with their mission to focus resources on the most promising programs to achieve that ultimate goal. You can find a deeper dive into their cost management and financial runway by checking out Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors.

Core Component 1: Harnessing Gamma-Delta T Cells

The first core component of IN8bio's mission is its singular focus on gamma-delta T cells ($\gamma\delta$ T cells). This is a strategic bet on a unique type of immune cell that can naturally differentiate between healthy and diseased tissue, offering a potential path to powerful cancer fighting with fewer side effects than traditional T cell therapies. This specialization is the foundation of their entire platform.

This focus is operationalized through their proprietary DeltEx™ platform, which allows for the ex vivo (outside the body) expansion and activation of these cells for use in both allogeneic (donor-derived) and autologous (patient-derived) treatments. The commitment to this technology is defintely a high-risk, high-reward strategy. It's a clear, non-cliched focus.

• Target cancer cells with precision.
• Develop therapies with favorable safety profiles.
• Leverage the unique properties of $\gamma\delta$ T cells.

Core Component 2: Pioneering Innovation for CANCER ZERO™

The mission's second pillar is the commitment to 'Pioneering Innovation,' which is the engine driving their vision of CANCER ZERO™-the elimination of all cancer cells in every patient. This means pushing beyond incremental improvements to seek transformative results. The company is not just trying to extend life; it's trying to cure the disease.

The clinical data from 2025 provides concrete evidence of this pioneering spirit. In the Phase 1 trial for INB-200 in newly-diagnosed glioblastoma (GBM) patients, those receiving multiple doses achieved a median Progression-Free Survival (mPFS) of 16.1 months as of May 31, 2025. This is more than double the 6.9 months typically seen with the standard-of-care Stupp protocol, showing a clear, innovative leap. Here's the quick math: they're more than doubling the time patients live without their cancer progressing, which is a massive win in this aggressive cancer.

Core Component 3: Delivering Durable, Patient-Centric Outcomes

The final, and most crucial, component is the commitment to the patient, focusing on delivering durable and safe outcomes. A therapy is only truly successful if it is effective and tolerable. This is where the safety profile of their $\gamma\delta$ T cell therapies becomes a key differentiator, translating the scientific mission into a human benefit.

The data from the INB-100 Phase 1 trial for high-risk Acute Myeloid Leukemia (AML) patients is a powerful example. As of January 17, 2025, 100% of treated AML patients remained relapse-free with a median follow-up of 20.1 months. Crucially, the trial has reported a favorable safety profile with no cases of cytokine release syndrome (CRS) or neurotoxicity (ICANS) to date. This unique safety profile-which avoids the severe toxicities common with other T cell therapies-is the direct result of their mission to create more accessible and safer treatments. That low toxicity risk changes the entire treatment calculus for doctors and patients.

IN8bio, Inc. (INAB) Vision Statement

You're looking for the hard truth behind the mission of a clinical-stage biotech like IN8bio, Inc. (INAB), not just the marketing copy. The direct takeaway is that their vision is a singular, aggressive target-CANCER ZERO-and their 2025 financials show a focused, albeit cash-constrained, execution against that goal, prioritizing clinical momentum over immediate profitability.

This isn't a company looking for incremental gains. Their entire strategic framework is built around a vision of 'CANCER ZERO - the elimination of all cancer cells in every patient battling the disease.' That's a massive, almost existential bet on their core technology, the DeltEx™ platform, which is why the near-term clinical data is so much more important than their current burn rate.

If you want to understand the full context of their journey, including the foundational science, you should review IN8bio, Inc. (INAB): History, Ownership, Mission, How It Works & Makes Money.

The Audacious Goal: CANCER ZERO

The mission of CANCER ZERO is the north star for every dollar IN8bio spends. It means aiming for complete eradication, not just tumor reduction, which is a critical distinction in the cellular therapy space. This focus is why their lead programs target aggressive diseases like Glioblastoma (GBM) and high-risk leukemias, where current standard-of-care treatments leave enormous unmet needs. They are defintely swinging for the fences.

For example, the positive Phase 1 data for their INB-200 program in newly diagnosed GBM showed a median Progression-Free Survival (mPFS) of 16.1 months as of May 31, 2025. That's more than double the typical 6.9 months seen with the standard Stupp protocol. That kind of clinical leap aligns directly with the 'elimination' part of their vision, showing a meaningful impact on patient outcomes.

• Target aggressive cancers, not just common ones.
• Seek complete eradication, not just disease control.

The Technology Engine: DeltEx™ Platform

The vehicle for this vision is their DeltEx™ platform, which harnesses the unique power of gamma-delta T cells. These are a specialized population of immune cells that naturally differentiate between healthy and diseased tissue, acting as a bridge between the innate and adaptive immune systems.

The company is advancing a multi-pronged pipeline using this technology: allogeneic (donor-derived, like INB-100), autologous (patient-derived, like INB-200), and genetically modified approaches. The expansion of the INB-100 Phase 1 trial to The Ohio State University in late 2025 is a clear operational move to accelerate patient enrollment and de-risk the program. Plus, the new preclinical data on their gamma-delta T cell engager, INB-619, showed potency comparable to FDA-approved CD19/CD20 engagers, but with minimal cytokine release, suggesting a potentially safer profile. That's a huge competitive advantage in the T-cell engager market.

Values Driving the Science: Patient-First Innovation

While IN8bio doesn't publish a bulleted list of 'Core Values,' their actions and stated mission imply a deep commitment to three key areas: Patient-Centricity, Scientific Excellence, and Innovation. You see this in their focus on aggressive cancers where patients have few options, and in their willingness to be the first to bring genetically modified gamma-delta T cells into the clinic.

Their approach is to push the boundaries of science, not settle for incremental improvements. The management team is committed to 'advancing therapeutic options for patients suffering from aggressive cancers that lack effective therapies.' That's the ethical mandate driving the financial and clinical risk they take. It's a high-risk, high-reward model, but the reward is life-saving, which is why the market tolerates the current cash burn. The focus is on deep, lasting responses.

The Financial Reality: Fueling the 2025 Pipeline

For a clinical-stage biotech, the financials map directly to the ability to execute the vision. As of September 30, 2025, IN8bio reported a cash balance of $10.7 million. This is the fuel for the CANCER ZERO mission.

Here's the quick math on their operating expenses for the third quarter of 2025:

• Research and Development (R&D) expenses were $2.1 million.
• General and Administrative (G&A) expenses were $1.9 million.
• Total net loss for the quarter was $3.9 million, or $0.85 per share.

The good news is that the net loss improved significantly from the prior year, reflecting tighter spending and pipeline prioritization. Still, with a quarterly net loss near $4 million, that $10.7 million cash balance gives them a limited runway, which is typical for a company with imminent, high-value clinical milestones. The next 12 months are critical; they need positive data from the upcoming SNO and ASH presentations to attract new capital and keep the CANCER ZERO vision on track.

IN8bio, Inc. (INAB) Core Values

You're looking for a clear read on IN8bio, Inc.'s operational DNA, and that's smart. A company's true values aren't just words on a website; they are the actions that drive capital allocation and clinical strategy. For IN8bio, the core commitment is simple: achieving CANCER ZERO-the elimination of all cancer cells in every patient battling the disease. This mission anchors their three principal, demonstrated values: Patient-Centric Innovation, Scientific Excellence, and Fiscal Responsibility.

This is a clinical-stage biotech, so their values map directly to how they develop their gamma-delta T cell therapies. You can see their commitment in the clinical data and the disciplined management of their R&D spend. It's about being precise with the science and the money.

Patient-Centric Innovation: Driving for Durable Remissions

The first value is a deep focus on the patient outcome, which for IN8bio means pursuing durable, relapse-free survival (RFS). They aren't just looking for a temporary fix; they are aiming for a cure, which is what CANCER ZERO means in practice. This commitment is why the company expanded its Phase 1 INB-100 trial to The Ohio State University in late 2025-to accelerate patient enrollment and speed up access to a potentially life-saving therapy.

The results from the INB-100 program in high-risk Acute Myeloid Leukemia (AML) patients undergoing bone marrow transplantation are a concrete example of this value in action. As of January 17, 2025, 100% of the treated AML patients remained relapse-free, with a median follow-up of 20.1 months. That's a powerful number. Also, in their INB-200 trial for newly diagnosed glioblastoma (GBM), patients receiving multiple doses achieved a median Progression-Free Survival (mPFS) of 16.1 months as of May 31, 2025, which is more than double the 6.9 months typically seen with the standard-of-care Stupp protocol. They are defintely moving the needle for patients with urgent unmet needs.

• Accelerate patient enrollment for faster therapy access.
• Demonstrate durable, relapse-free survival in clinical trials.
• Target cancers with the highest unmet medical need.

You can see more on their pipeline and market position by Exploring IN8bio, Inc. (INAB) Investor Profile: Who's Buying and Why?

Scientific Excellence: Advancing the DeltEx™ Platform

Scientific excellence is the engine of a biotech company, and IN8bio grounds this value in its proprietary DeltEx™ platform. This is about being the leader in gamma-delta T cell therapy, focusing on a unique immune cell population that naturally differentiates between healthy and diseased tissue. Their commitment here is to innovation that translates to a safer, more effective product.

In 2025, the company presented new preclinical data on their novel gamma-delta T cell engager, INB-619, which showed it could achieve B cell elimination comparable to FDA-approved products but with minimal cytokine release. This is a critical safety advantage. Plus, their manufacturing prowess was recognized with the Host Region USA East Abstract Award at the ISCT 2025 Annual Meeting. This award validates the robustness of their manufacturing process, which is crucial for scalable, consistent cell therapies.

• Pioneer gamma-delta T cell engineering and manufacturing.
• Develop therapies with improved safety profiles.
• Gain external recognition for platform technology.

Fiscal Responsibility: Disciplined Capital Allocation

For a clinical-stage company, fiscal responsibility is a core value that directly impacts its ability to deliver on its mission. It's about stretching every dollar to maximize clinical progress. IN8bio has demonstrated this value through strategic pipeline prioritization, which has led to significant cost reductions in 2025.

Here's the quick math on their Q3 2025 results: Research and Development (R&D) expenses dropped to $2.1 million, down from $3.3 million in the comparable prior year period. General and Administrative (G&A) expenses also fell to $1.9 million from $2.7 million year-over-year. This operational discipline helped improve the net loss to $3.9 million in Q3 2025, compared to a $7.1 million loss in Q3 2024. What this estimate hides is the strategic decision to pause certain activities, which is what extended their cash runway into June 2026. As of September 30, 2025, their cash position stood at $10.7 million.

• Reduce R&D and G&A expenses year-over-year.
• Extend cash runway through strategic prioritization.
• Improve net loss quarter-over-quarter.